$IRWD

IRONWOOD PHARMACEUTICALS INC

Runway:cash-flow +

NasdaqMarket cap: —CIK 0001446847

Upcoming catalysts

0 surfaced

No catalysts surfaced for IRWD yet.

IW-3718

Gastroesophageal Reflux Disease

IW-9179

Diabetic Gastroparesis

MD-7246

Irritable Bowel Syndrome With Diarrhea (IBS-D)

IW-6118

Healthy

IW-3300

Healthy Volunteers

Microgestin®

Healthy Volunteers

Linaclotide Acetate

Irritable Bowel Syndrome With Constipation

IW-3300 rectal foam

Interstitial Cystitis

Lesinurad

Gout

Linaclotide or Matching Placebo

Irritable Bowel Syndrome With Constipation

Matching Placebo

Chronic Constipation

Linaclotide

Irritable Bowel Syndrome Characterized by Constipation

MD-1100 Acetate

Irritable Bowel Syndrome

MD-0727

Hypercholesterolemia

NCT	Drug	Phase	Status	Primary completion
NCT05740007	IW-3300 rectal foam	Phase 2	Terminated	2025-01-23
NCT05362695	IW-3300	Phase 1	Completed	2022-06-30
NCT05188261	IW-3300	Phase 1	Completed	2022-03-09
NCT03561090	IW-3718	Phase 3	Terminated	2020-10-07
NCT03561883	IW-3718	Phase 3	Completed	2020-07-28
NCT03931785	MD-7246	Phase 2	Completed	2020-02-26
NCT03856970	Microgestin®	Phase 1	Completed	2019-06-25
NCT03573908	Linaclotide	Phase 3	Completed	2019-03-13
NCT03226899	Lesinurad	Phase 4	Terminated	2019-02-25
NCT02837783	Linaclotide	Phase 4	Terminated	2018-10-31
NCT02637557	IW-3718	Phase 2	Completed	2017-04-26
NCT02559206	Linaclotide	Phase 2	Completed	2016-09-30
NCT02289846	IW-9179	Phase 2	Completed	2015-12-01
NCT02291679	Linaclotide	Phase 3	Completed	2015-08-01
NCT02030925	IW-3718	Phase 2	Completed	2014-12-01
NCT01712412	IW-9179	Phase 2	Terminated	2014-02-01
NCT00730171	Linaclotide	Phase 3	Completed	2012-03-01
NCT00938717	Linaclotide or Matching Placebo	Phase 3	Completed	2010-09-01
NCT01107236	IW-6118	Phase 2	Completed	2010-08-01
NCT00730015	Matching Placebo	Phase 3	Completed	2009-08-01